第8章 各用途的市場分類

第9章 單株抗體的各種類的市場分類

第10章 客戶形勢

第11章 地區形勢

第12章 決策架構

第13章 市場成長因素與課題

市場成長因素

市場課題

第14章 市場趨勢

第15章 業者情勢

概要

創造性破壞狀況

第16章 供應商分析

交易廠商

供應商分類

供應商的市場定位

AbbVie

Amgen

Johnson & Johnson

Merck

第17章 附錄

簡稱清單

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Product Code: IRTNTR21977

About this market:

Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies. Technavio's analysts have predicted that the monoclonal antibodies market will register a CAGR of about 15% by 2022.

Market Overview:

Introduction of low cost biosimilar monoclonal antibodies

The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.

High cost of monoclonal antibodies

Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.

For the detailed list of factors that will drive and challenge the growth of the monoclonal antibodies market during the 2019-2023, view our report.

Competitive Landscape:

The market appears to be fragmented and with the presence of several companies including Johnson & Johnson and Merck the competitive environment is quite intense. Factors such as the rise in the number of companies venturing into monoclonal antibodies space and the introduction of low cost biosimilar monoclonal antibodies, will provide considerable growth opportunities to monoclonal antibodies manufactures. AbbVie, Amgen, Johnson & Johnson, and Merck are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition

Market sizing 2017

Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 08: MARKET SEGMENTATION BY APPLICATION

Segmentation by application

Comparison by application

Oncology - Market size and forecast 2017-2022

Immunology - Market size and forecast 2017-2022

Hematology - Market size and forecast 2017-2022

Others - Market size and forecast 2017-2022

Market opportunity by application

PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIES

Segmentation by origin of monoclonal antibodies

Murine antibodies

Human antibodies

Humanized antibodies

Chimeric antibodies

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation

Regional comparison

Americas - Market size and forecast 2017-2022

EMEA - Market size and forecast 2017-2022

APAC - Market size and forecast 2017-2022

Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 14: MARKET TRENDS

Increasing cases of diseases like cancer and immunological disorders

Rise in the number of companies venturing into the monoclonal antibodies space